Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001144204-19-039648
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-08-13 18:07:20
Reporting Period:
2019-08-09
Accepted Time:
2019-08-13 18:07:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1023024 Ani Pharmaceuticals Inc ANIP Pharmaceutical Preparations (2834) 582301143
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1109507 Meridian Venture Partners Ii Lp 259 N. Radnor-Chester Road
Suite 130
Radnor PA 19087
No No Yes No
1579672 Jr E. Robert Brown C/o Ani Pharmaceuticals, Inc.
210 Main Street West
Baudette MN 56623
Yes No No No
1580169 Meridian Venture Partners Ii, Co. 259 N. Radnor-Chester Road
Suite 130
Radnor PA 19087
No No Yes No
1580170 Meridian Venture Partners Ii Gp, L.p. 259 N. Radnor-Chester Road
Suite 130
Radnor PA 19087
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-08-09 19,860 $71.70 2,330,699 No 4 S Direct
Common Stock Disposition 2019-08-12 21,016 $71.45 2,309,683 No 4 S Direct
Common Stock Disposition 2019-08-13 20,821 $71.77 2,288,862 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price, rounded to the nearest cent. The shares were sold pursuant to a Rule 10b5-1 diversification plan entered into by the Reporting Person on June 6, 2019. The shares were sold in multiple transactions at prices ranging from $70.84 to $71.78 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by the Reporting Person at each separate price on each date of sale.
  2. The price reported in Column 4 is a weighted average price, rounded to the nearest cent. The shares were sold pursuant to a Rule 10b5-1 diversification plan entered into by the Reporting Person on June 6, 2019. The shares were sold in multiple transactions at prices ranging from $70.25 to $72.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by the Reporting Person at each separate price on each date of sale.
  3. The price reported in Column 4 is a weighted average price, rounded to the nearest cent. The shares were sold pursuant to a Rule 10b5-1 diversification plan entered into by the Reporting Person on June 6, 2019. The shares were sold in multiple transactions at prices ranging from $71.15 to $73.45 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by the Reporting Person at each separate price on each date of sale.
  4. Meridian Venture Partners II, Co. (MVP Corp.) is the general partner of Meridian Venture Partners II GP, L.P. (GP), the general partner of Meridian Venture Partners II, L.P. (MVP II). Robert E. Brown, Jr., a director of the issuer, is the President, sole stockholder and sole director of MVP Corp., as well as a limited partner of GP and one of two principals of MVP II.